CinCor Pharma, a Phase 2 biotech focused on treatments for hypertension and other cardio-renal diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company's lead candidate, CIN-107, has been designed to use a differentiated mechanism of action, direct inhibition of aldosterone synthase production, with the goal of providing an improved treatment for patients suffering from hypertension, or high blood pressure. Earlier this year, CinCor Pharma initiated several different trials for patients suffering from hypertension as well as primary aldosteronism, or PA. The company is also exploring its utility in ameliorating complications of chronic kidney disease, or CKD, with plans to initiate trials in the first half of 2022.
The Boston, MA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol CINC. Morgan Stanley, Jefferies, and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
